74 related articles for article (PubMed ID: 8005855)
1. NG-methyl-L-arginine, an inhibitor of nitric oxide formation, reverses IL-2-mediated hypotension in dogs.
Kilbourn RG; Owen-Schaub LB; Cromeens DM; Gross SS; Flaherty MJ; Santee SM; Alak AM; Griffith OW
J Appl Physiol (1985); 1994 Mar; 76(3):1130-7. PubMed ID: 8005855
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of interleukin-1-alpha-induced nitric oxide synthase in vascular smooth muscle and full reversal of interleukin-1-alpha-induced hypotension by N omega-amino-L-arginine.
Kilbourn RG; Gross SS; Lodato RF; Adams J; Levi R; Miller LL; Lachman LB; Griffith OW
J Natl Cancer Inst; 1992 Jul; 84(13):1008-16. PubMed ID: 1376778
[TBL] [Abstract][Full Text] [Related]
3. Strategies to reduce side effects of interleukin-2: evaluation of the antihypotensive agent NG-monomethyl-L-arginine.
Kilbourn RG; Fonseca GA; Trissel LA; Griffith OW
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S21-30. PubMed ID: 10685654
[TBL] [Abstract][Full Text] [Related]
4. NG-methyl-L-arginine, an inhibitor of nitric oxide synthase, reverses interleukin-2-induced hypotension.
Kilbourn RG; Fonseca GA; Griffith OW; Ewer M; Price K; Striegel A; Jones E; Logothetis CJ
Crit Care Med; 1995 Jun; 23(6):1018-24. PubMed ID: 7774211
[TBL] [Abstract][Full Text] [Related]
5. NG-methyl-L-arginine, an inhibitor of nitric oxide formation, acts synergistically with dobutamine to improve cardiovascular performance in endotoxemic dogs.
Kilbourn RG; Cromeens DM; Chelly FD; Griffith OW
Crit Care Med; 1994 Nov; 22(11):1835-40. PubMed ID: 7956289
[TBL] [Abstract][Full Text] [Related]
6. NG-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide.
Kilbourn RG; Gross SS; Jubran A; Adams J; Griffith OW; Levi R; Lodato RF
Proc Natl Acad Sci U S A; 1990 May; 87(9):3629-32. PubMed ID: 2333306
[TBL] [Abstract][Full Text] [Related]
7. Nitric oxide inhibition attenuates systemic hypotension produced by protamine.
Raikar GV; Hisamochi K; Raikar BL; Schaff HV
J Thorac Cardiovasc Surg; 1996 Jun; 111(6):1240-6; discussion 1246-7. PubMed ID: 8642826
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular actions of NG-methyl-L-arginine are abolished in a canine shock model using high-dose endotoxin.
Klabunde RE; Helgren MC
Res Commun Chem Pathol Pharmacol; 1992 Oct; 78(1):57-68. PubMed ID: 1462049
[TBL] [Abstract][Full Text] [Related]
9. Reversal of endotoxin-mediated shock by NG-methyl-L-arginine, an inhibitor of nitric oxide synthesis.
Kilbourn RG; Jubran A; Gross SS; Griffith OW; Levi R; Adams J; Lodato RF
Biochem Biophys Res Commun; 1990 Nov; 172(3):1132-8. PubMed ID: 2244897
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular effects of NG-methyl-L-arginine in chronically instrumented conscious dogs.
Lechevalier T; Doursout MF; Chelly JE; Kilbourn RG
J Appl Physiol (1985); 1994 Jul; 77(1):471-5. PubMed ID: 7525530
[TBL] [Abstract][Full Text] [Related]
11. NG-monomethyl-l-arginine (NMA) restores arterial blood pressure but reduces cardiac output in a canine model of endotoxic shock.
Klabunde RE; Ritger RC
Biochem Biophys Res Commun; 1991 Aug; 178(3):1135-40. PubMed ID: 1872835
[TBL] [Abstract][Full Text] [Related]
12. Protective effect of NG-monomethyl-L-arginine against hypotension inducted by combined tumour necrosis factor-alpha and whole body hyperthermia in rats.
Makino M; Lodato RF; Stephens LC; Strebel FR; Jenkins G; Ohno S; Sakaguchi Y; Kostergaard J; Tomasovic SP; Bull JM
Int J Hyperthermia; 1996; 12(5):617-34. PubMed ID: 8886889
[TBL] [Abstract][Full Text] [Related]
13. NG-methyl-L-arginine restores arterial pressure in hemorrhaged rats.
Klabunde RE; Slayton KJ; Ritger RC
Circ Shock; 1993 May; 40(1):47-52. PubMed ID: 8324889
[TBL] [Abstract][Full Text] [Related]
14. Effects of N(g)-methyl-L-arginine, an inhibitor of nitric oxide synthesis, on interleukin-2-induced capillary leakage and antitumor responses in healthy and tumor-bearing mice.
Orucevic A; Lala PK
Cancer Immunol Immunother; 1996 Jan; 42(1):38-46. PubMed ID: 8625365
[TBL] [Abstract][Full Text] [Related]
15. Inducible nitric oxide synthase (iNOS) is not required for IL-2-induced hypotension and vascular leak syndrome in mice.
Kondapaneni M; McGregor JR; Salvemini D; Laubach VE; Samlowski WE
J Immunother; 2008 May; 31(4):325-33. PubMed ID: 18391763
[TBL] [Abstract][Full Text] [Related]
16. Altered nitric oxide production and exogenous nitric oxide do not affect the proliferation of rat mesangial cells.
Mohaupt M; Schoecklmann HO; Schulze-Lohoff E; Sterzel RB
J Hypertens; 1994 Apr; 12(4):401-8. PubMed ID: 8064164
[TBL] [Abstract][Full Text] [Related]
17. Effects of N(G)-Nitro-L-arginine methyl ester, an inhibitor of nitric oxide synthesis, on IL-2-induced LAK cell generation in vivo and in vitro in healthy and tumor-bearing mice.
Orucevic A; Lala PK
Cell Immunol; 1996 Apr; 169(1):125-32. PubMed ID: 8612285
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and toxicity of protracted nitric oxide synthesis inhibition during IL-2 treatment of mice.
Samlowski WE; Yim CY; McGregor JR; Kwon OD; Gonzales S; Hibbs JB
J Immunother Emphasis Tumor Immunol; 1995 Oct; 18(3):166-78. PubMed ID: 8770772
[TBL] [Abstract][Full Text] [Related]
19. Effects of NG-methyl-L-arginine, NG-nitro-L-arginine, and aminoguanidine on constitutive and inducible nitric oxide synthase in rat aorta.
Joly GA; Ayres M; Chelly F; Kilbourn RG
Biochem Biophys Res Commun; 1994 Feb; 199(1):147-54. PubMed ID: 7510104
[TBL] [Abstract][Full Text] [Related]
20. Nitric oxide synthesis contributes to IL-2-induced antitumor responses against intraperitoneal Meth A tumor.
Yim CY; McGregor JR; Kwon OD; Bastian NR; Rees M; Mori M; Hibbs JB; Samlowski WE
J Immunol; 1995 Nov; 155(9):4382-90. PubMed ID: 7594598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
